Johnson & Johnson Is Becoming a Growth Stock: Does AbbVie Make JNJ Look Expensive?
FROM THE WIRE · FINANCE.YAHOO.COM
Johnson & Johnson (NYSE:JNJ) is starting to look less like a defensive healthcare giant and more like a growth story. The harder question is how much investors should pay before that growth fully arrives. The company raised its 2026 outlook after second-quarter sales increased…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishJNJ raised 2026 guidance and shows accelerating growth prospects, justifying a valuation premium.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Johnson & Johnson raised 2026 guidance after Q2 sales increased 6.6% to $25.3 billion.
- 02Adjusted EPS rose 4.7% to $2.90, with full-year guidance increased to $11.60-$11.75.
- 03JNJ is on track to cross $100 billion in annual revenue for the first time.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Johnson & Johnson258.45 USDMarket closedtoday +1.44%Positive AbbVie Inc.271.36 USDMarket closedtoday +1.75%Neutral Eli Lilly and Company1,188.72 USDMarket closedtoday +2.70%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets